OptiNose Expects FY23 XHANCE Net Revenues Of $64M-$70M (Prior View: $62M-$68M)
Portfolio Pulse from Benzinga Newsdesk
OptiNose, Inc. has updated its forecast for FY23 XHANCE net revenues to $64M-$70M, up from the previous estimate of $62M-$68M. The company also expects the average net revenue per prescription to be around $200.
August 10, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OptiNose has increased its FY23 revenue forecast for XHANCE, which could indicate a positive outlook for the company's performance.
OptiNose has raised its revenue forecast for FY23, which is generally a positive sign indicating that the company expects better performance in the future. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100